@entity6786 XXXX is associated with smoking cessation in varenicline therapy.

@entity1 @entity59092 @entity63862 @entity71339 @entity15564 @entity6786 @entity17378 @entity71338 @entity734
BACKGROUND: The large individual variability in response to drugs for smoking cessation suggests that specific treatments can be more effective in particular subgroups of smokers. In the context of personalized medicine, the main aim of the present study was to evaluate whether the @entity6786 and @entity15564 polymorphisms are associated with response to smoking cessation therapies in @entity1 from a smoker assistance program. METHODS: This cohort study enrolled 483 smoking @entity1 who received behavioral counseling and drug treatment (varenicline, bupropion, and/or nicotine replacement therapy). Smoking cessation success was considered for @entity1 who completed 6 months of continuous abstinence. Fagerstr  m test for nicotine @entity734 ( @entity17378 ) and Issa situational smoking scores were analyzed for nicotine @entity734 . The @entity6786 ( @entity59092 and @entity63862 ) and @entity15564 ( @entity71338 and @entity71339 ) polymorphisms were genotyped by high resolution melting analysis. RESULTS: @entity1 with @entity59092 CC genotype had lower success rate in treatment with varenicline (29.5%) compared with carriers of CT or TT genotypes (50.9%; p = 0.007, n = 167). The CT or TT genotypes were associated with higher odds ratio for success (OR = 1.67, 95% CI = 1.10-2.53, p = 0.02), in a multivariate model. We did not observe significant differences in the @entity17378 and Issa scores according to the studied polymorphisms. CONCLUSION: The @entity6786 @entity59092 is associated with smoking cessation in individuals on varenicline therapy. We suggest that this polymorphism influences the varenicline response, but replications of this finding are needed.
